Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

The immunocytokine NHS-IL12 is targeted to necrotic tumour areas to prompt an immune response. Authors show here in mouse colon and breast models that the combination of histone deacetylase inhibitor, Entinostat, and NHS-IL12 generates a tumour microenvironment that favours tumour resolution.

Guardado en:

Detalles Bibliográficos
Autores principales:	Kristin C. Hicks, Paul L. Chariou, Yohei Ozawa, Christine M. Minnar, Karin M. Knudson, Thomas J. Meyer, Jing Bian, Margaret Cam, Jeffrey Schlom, Sofia R. Gameiro
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/9ae4f4dff32d41159c913dd23783fab3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ae4f4dff32d41159c913dd23783fab3
record_format	dspace
spelling	oai:doaj.org-article:9ae4f4dff32d41159c913dd23783fab32021-12-02T15:09:09ZTumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape10.1038/s41467-021-25393-x2041-1723https://doaj.org/article/9ae4f4dff32d41159c913dd23783fab32021-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25393-xhttps://doaj.org/toc/2041-1723The immunocytokine NHS-IL12 is targeted to necrotic tumour areas to prompt an immune response. Authors show here in mouse colon and breast models that the combination of histone deacetylase inhibitor, Entinostat, and NHS-IL12 generates a tumour microenvironment that favours tumour resolution.Kristin C. HicksPaul L. ChariouYohei OzawaChristine M. MinnarKarin M. KnudsonThomas J. MeyerJing BianMargaret CamJeffrey SchlomSofia R. GameiroNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Kristin C. Hicks Paul L. Chariou Yohei Ozawa Christine M. Minnar Karin M. Knudson Thomas J. Meyer Jing Bian Margaret Cam Jeffrey Schlom Sofia R. Gameiro Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
description	The immunocytokine NHS-IL12 is targeted to necrotic tumour areas to prompt an immune response. Authors show here in mouse colon and breast models that the combination of histone deacetylase inhibitor, Entinostat, and NHS-IL12 generates a tumour microenvironment that favours tumour resolution.
format	article
author	Kristin C. Hicks Paul L. Chariou Yohei Ozawa Christine M. Minnar Karin M. Knudson Thomas J. Meyer Jing Bian Margaret Cam Jeffrey Schlom Sofia R. Gameiro
author_facet	Kristin C. Hicks Paul L. Chariou Yohei Ozawa Christine M. Minnar Karin M. Knudson Thomas J. Meyer Jing Bian Margaret Cam Jeffrey Schlom Sofia R. Gameiro
author_sort	Kristin C. Hicks
title	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
title_short	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
title_full	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
title_fullStr	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
title_full_unstemmed	Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
title_sort	tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9ae4f4dff32d41159c913dd23783fab3
work_keys_str_mv	AT kristinchicks tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT paullchariou tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT yoheiozawa tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT christinemminnar tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT karinmknudson tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT thomasjmeyer tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT jingbian tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT margaretcam tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT jeffreyschlom tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape AT sofiargameiro tumourtargetedinterleukin12andentinostatcombinationtherapyimprovescancersurvivalbyreprogrammingthetumourimmunecelllandscape
_version_	1718387891240960000

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Ejemplares similares